Table 2 Costs detail for the different categories
From: Economic impact of a more extensive use of FENO testing on the Italian population with asthma
Cost Category | Strategy SOC | Strategy FENO | Difference % |
|---|---|---|---|
Exacerbations | |||
Hospitalizations for serious exacerbations | 31,648,508 € | 5,380,246 € | -83% |
Management of non-serious exacerbations | 168,976,433 € | 119,973,268 € | -29% |
Total exacerbations | 200,624,942 € | 125,353,514 € | -38% |
Treatments | |||
Corticosteroids for inhalation and combinations | 663,200,000 € | 384,656,000 € | -42% |
Other drugs | 317,500,000 € | 317,500,000 € | 0% |
Total treatments | 980,700,000 € | 702,156,000 € | -28% |
Management of adverse events | |||
Sepsis | 28,485,156 € | 19,748,806 € | -31% |
Venous thromboembolism | 3,812,104 € | 2,642,938 € | -31% |
Fractures | 71,282,080 € | 49,419,985 € | -31% |
Total management of adverse events | 103,579,340 € | 71,811,729 € | -31% |
Visits | |||
Total cost for visits | 126,663,687 € | 126,663,687 € | 0% |
Total cost for spirometries | 187,649,907 € | 187,649,907 € | 0% |
FENO test | 0 € | 181,394,910 € | 100% |
Total visits | 314,313,594 € | 495,708,504 € | 58% |
OVERALL TOTAL | 1,599,217,876 € | 1,395,029,747 € | -13% |